JP2011514522A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2011514522A5 JP2011514522A5 JP2010547852A JP2010547852A JP2011514522A5 JP 2011514522 A5 JP2011514522 A5 JP 2011514522A5 JP 2010547852 A JP2010547852 A JP 2010547852A JP 2010547852 A JP2010547852 A JP 2010547852A JP 2011514522 A5 JP2011514522 A5 JP 2011514522A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- analytes
- combinations
- activation state
- agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 238000000034 method Methods 0.000 claims 25
- 230000004913 activation Effects 0.000 claims 15
- 239000002246 antineoplastic agent Substances 0.000 claims 13
- 206010006187 Breast cancer Diseases 0.000 claims 11
- 208000026310 Breast neoplasm Diseases 0.000 claims 11
- 230000003321 amplification Effects 0.000 claims 10
- 238000003199 nucleic acid amplification method Methods 0.000 claims 10
- 210000004027 cell Anatomy 0.000 claims 9
- 206010028980 Neoplasm Diseases 0.000 claims 8
- 239000003153 chemical reaction reagent Substances 0.000 claims 5
- 230000001419 dependent effect Effects 0.000 claims 5
- 210000001519 tissue Anatomy 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 4
- 238000001514 detection method Methods 0.000 claims 4
- 238000010790 dilution Methods 0.000 claims 4
- 239000012895 dilution Substances 0.000 claims 4
- 230000011664 signaling Effects 0.000 claims 4
- 239000007787 solid Substances 0.000 claims 4
- 108010015776 Glucose oxidase Proteins 0.000 claims 3
- 239000004366 Glucose oxidase Substances 0.000 claims 3
- 102000003992 Peroxidases Human genes 0.000 claims 3
- 108010090804 Streptavidin Proteins 0.000 claims 3
- -1 cKit Proteins 0.000 claims 3
- 210000003040 circulating cell Anatomy 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229940116332 glucose oxidase Drugs 0.000 claims 3
- 235000019420 glucose oxidase Nutrition 0.000 claims 3
- 108040007629 peroxidase activity proteins Proteins 0.000 claims 3
- QFJCIRLUMZQUOT-HPLJOQBZSA-N sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 2
- BJHCYTJNPVGSBZ-YXSASFKJSA-N 1-[4-[6-amino-5-[(Z)-methoxyiminomethyl]pyrimidin-4-yl]oxy-2-chlorophenyl]-3-ethylurea Chemical compound CCNC(=O)Nc1ccc(Oc2ncnc(N)c2\C=N/OC)cc1Cl BJHCYTJNPVGSBZ-YXSASFKJSA-N 0.000 claims 2
- VZWXNOBHWODXCW-ZOBUZTSGSA-N 5-[(3as,4s,6ar)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]-n-[2-(4-hydroxyphenyl)ethyl]pentanamide Chemical compound C1=CC(O)=CC=C1CCNC(=O)CCCC[C@H]1[C@H]2NC(=O)N[C@H]2CS1 VZWXNOBHWODXCW-ZOBUZTSGSA-N 0.000 claims 2
- 108010001336 Horseradish Peroxidase Proteins 0.000 claims 2
- 239000005551 L01XE03 - Erlotinib Substances 0.000 claims 2
- 239000002147 L01XE04 - Sunitinib Substances 0.000 claims 2
- 239000002136 L01XE07 - Lapatinib Substances 0.000 claims 2
- 101100335081 Mus musculus Flt3 gene Proteins 0.000 claims 2
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 2
- 102000007399 Nuclear hormone receptor Human genes 0.000 claims 2
- 108020005497 Nuclear hormone receptor Proteins 0.000 claims 2
- 108010053096 Vascular Endothelial Growth Factor Receptor-1 Proteins 0.000 claims 2
- 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 claims 2
- 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 claims 2
- 102100033178 Vascular endothelial growth factor receptor 1 Human genes 0.000 claims 2
- 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims 2
- 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 claims 2
- 238000003556 assay Methods 0.000 claims 2
- 238000004040 coloring Methods 0.000 claims 2
- 229940127089 cytotoxic agent Drugs 0.000 claims 2
- 229940079593 drug Drugs 0.000 claims 2
- AAKJLRGGTJKAMG-UHFFFAOYSA-N erlotinib Chemical compound C=12C=C(OCCOC)C(OCCOC)=CC2=NC=NC=1NC1=CC=CC(C#C)=C1 AAKJLRGGTJKAMG-UHFFFAOYSA-N 0.000 claims 2
- XGALLCVXEZPNRQ-UHFFFAOYSA-N gefitinib Chemical group C=12C=C(OCCCN3CCOCC3)C(OC)=CC2=NC=NC=1NC1=CC=C(F)C(Cl)=C1 XGALLCVXEZPNRQ-UHFFFAOYSA-N 0.000 claims 2
- YLMAHDNUQAMNNX-UHFFFAOYSA-N imatinib methanesulfonate Chemical compound CS(O)(=O)=O.C1CN(C)CCN1CC1=CC=C(C(=O)NC=2C=C(NC=3N=C(C=CN=3)C=3C=NC=CC=3)C(C)=CC=2)C=C1 YLMAHDNUQAMNNX-UHFFFAOYSA-N 0.000 claims 2
- BCFGMOOMADDAQU-UHFFFAOYSA-N lapatinib Chemical compound O1C(CNCCS(=O)(=O)C)=CC=C1C1=CC=C(N=CN=C2NC=3C=C(Cl)C(OCC=4C=C(F)C=CC=4)=CC=3)C2=C1 BCFGMOOMADDAQU-UHFFFAOYSA-N 0.000 claims 2
- VHOGYURTWQBHIL-UHFFFAOYSA-N leflunomide Chemical compound O1N=CC(C(=O)NC=2C=CC(=CC=2)C(F)(F)F)=C1C VHOGYURTWQBHIL-UHFFFAOYSA-N 0.000 claims 2
- 239000007800 oxidant agent Substances 0.000 claims 2
- 229960001972 panitumumab Drugs 0.000 claims 2
- WBXPDJSOTKVWSJ-ZDUSSCGKSA-L pemetrexed(2-) Chemical group C=1NC=2NC(N)=NC(=O)C=2C=1CCC1=CC=C(C(=O)N[C@@H](CCC([O-])=O)C([O-])=O)C=C1 WBXPDJSOTKVWSJ-ZDUSSCGKSA-L 0.000 claims 2
- 238000001959 radiotherapy Methods 0.000 claims 2
- ZAHRKKWIAAJSAO-UHFFFAOYSA-N rapamycin Natural products COCC(O)C(=C/C(C)C(=O)CC(OC(=O)C1CCCCN1C(=O)C(=O)C2(O)OC(CC(OC)C(=CC=CC=CC(C)CC(C)C(=O)C)C)CCC2C)C(C)CC3CCC(O)C(C3)OC)C ZAHRKKWIAAJSAO-UHFFFAOYSA-N 0.000 claims 2
- 230000004044 response Effects 0.000 claims 2
- 229960004641 rituximab Drugs 0.000 claims 2
- 230000019491 signal transduction Effects 0.000 claims 2
- 229960002930 sirolimus Drugs 0.000 claims 2
- 210000000130 stem cell Anatomy 0.000 claims 2
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 claims 2
- 239000005483 tyrosine kinase inhibitor Substances 0.000 claims 2
- 150000004917 tyrosine kinase inhibitor derivatives Chemical class 0.000 claims 2
- 229960000241 vandetanib Drugs 0.000 claims 2
- UHTHHESEBZOYNR-UHFFFAOYSA-N vandetanib Chemical compound COC1=CC(C(/N=CN2)=N/C=3C(=CC(Br)=CC=3)F)=C2C=C1OCC1CCN(C)CC1 UHTHHESEBZOYNR-UHFFFAOYSA-N 0.000 claims 2
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical group CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 claims 1
- 229940122815 Aromatase inhibitor Drugs 0.000 claims 1
- ZEOWTGPWHLSLOG-UHFFFAOYSA-N Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F Chemical compound Cc1ccc(cc1-c1ccc2c(n[nH]c2c1)-c1cnn(c1)C1CC1)C(=O)Nc1cccc(c1)C(F)(F)F ZEOWTGPWHLSLOG-UHFFFAOYSA-N 0.000 claims 1
- 208000005443 Circulating Neoplastic Cells Diseases 0.000 claims 1
- 101100481404 Danio rerio tie1 gene Proteins 0.000 claims 1
- 101100481408 Danio rerio tie2 gene Proteins 0.000 claims 1
- HKVAMNSJSFKALM-GKUWKFKPSA-N Everolimus Chemical compound C1C[C@@H](OCCO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 HKVAMNSJSFKALM-GKUWKFKPSA-N 0.000 claims 1
- 108091008794 FGF receptors Proteins 0.000 claims 1
- 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 claims 1
- 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 claims 1
- 102100023600 Fibroblast growth factor receptor 2 Human genes 0.000 claims 1
- 101710182389 Fibroblast growth factor receptor 2 Proteins 0.000 claims 1
- 102100027842 Fibroblast growth factor receptor 3 Human genes 0.000 claims 1
- 101710182396 Fibroblast growth factor receptor 3 Proteins 0.000 claims 1
- 102100027844 Fibroblast growth factor receptor 4 Human genes 0.000 claims 1
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 claims 1
- 102100022623 Hepatocyte growth factor receptor Human genes 0.000 claims 1
- 101000917134 Homo sapiens Fibroblast growth factor receptor 4 Proteins 0.000 claims 1
- 101000972946 Homo sapiens Hepatocyte growth factor receptor Proteins 0.000 claims 1
- 101000974356 Homo sapiens Nuclear receptor coactivator 3 Proteins 0.000 claims 1
- 101001126417 Homo sapiens Platelet-derived growth factor receptor alpha Proteins 0.000 claims 1
- 101000579425 Homo sapiens Proto-oncogene tyrosine-protein kinase receptor Ret Proteins 0.000 claims 1
- 101001012157 Homo sapiens Receptor tyrosine-protein kinase erbB-2 Proteins 0.000 claims 1
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical group OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 claims 1
- 239000005517 L01XE01 - Imatinib Substances 0.000 claims 1
- 239000005411 L01XE02 - Gefitinib Substances 0.000 claims 1
- 101150097381 Mtor gene Proteins 0.000 claims 1
- 101100268648 Mus musculus Abl1 gene Proteins 0.000 claims 1
- 101100481410 Mus musculus Tek gene Proteins 0.000 claims 1
- 101100481406 Mus musculus Tie1 gene Proteins 0.000 claims 1
- 102000011244 Nuclear receptor coactivator Human genes 0.000 claims 1
- 108050001461 Nuclear receptor coactivator Proteins 0.000 claims 1
- 102100022883 Nuclear receptor coactivator 3 Human genes 0.000 claims 1
- 101100248186 Oryza sativa subsp. japonica RFT1 gene Proteins 0.000 claims 1
- 108091007960 PI3Ks Proteins 0.000 claims 1
- 102000038030 PI3Ks Human genes 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- 108010051742 Platelet-Derived Growth Factor beta Receptor Proteins 0.000 claims 1
- 102100030485 Platelet-derived growth factor receptor alpha Human genes 0.000 claims 1
- 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 claims 1
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims 1
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims 1
- 102100030086 Receptor tyrosine-protein kinase erbB-2 Human genes 0.000 claims 1
- 101000857870 Squalus acanthias Gonadoliberin Proteins 0.000 claims 1
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 claims 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 229960000548 alemtuzumab Drugs 0.000 claims 1
- 229940110282 alimta Drugs 0.000 claims 1
- 239000012491 analyte Substances 0.000 claims 1
- 239000003886 aromatase inhibitor Substances 0.000 claims 1
- 229940120638 avastin Drugs 0.000 claims 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 1
- 239000011324 bead Substances 0.000 claims 1
- 229960000397 bevacizumab Drugs 0.000 claims 1
- 229960002685 biotin Drugs 0.000 claims 1
- 235000020958 biotin Nutrition 0.000 claims 1
- 239000011616 biotin Substances 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 210000004369 blood Anatomy 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 229940112129 campath Drugs 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 229960005395 cetuximab Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 210000002358 circulating endothelial cell Anatomy 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 230000003511 endothelial effect Effects 0.000 claims 1
- 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 claims 1
- 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 claims 1
- 229940082789 erbitux Drugs 0.000 claims 1
- 229960001433 erlotinib Drugs 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 claims 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 claims 1
- 229960004039 finasteride Drugs 0.000 claims 1
- 239000012530 fluid Substances 0.000 claims 1
- 229960002584 gefitinib Drugs 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- 229960000578 gemtuzumab Drugs 0.000 claims 1
- 229960003297 gemtuzumab ozogamicin Drugs 0.000 claims 1
- 229940020967 gemzar Drugs 0.000 claims 1
- 239000011521 glass Substances 0.000 claims 1
- 229940080856 gleevec Drugs 0.000 claims 1
- XLXSAKCOAKORKW-AQJXLSMYSA-N gonadorelin Chemical compound C([C@@H](C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1[C@@H](CCC1)C(=O)NCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H]1NC(=O)CC1)C1=CC=C(O)C=C1 XLXSAKCOAKORKW-AQJXLSMYSA-N 0.000 claims 1
- 229940035638 gonadotropin-releasing hormone Drugs 0.000 claims 1
- 239000003102 growth factor Substances 0.000 claims 1
- 229940022353 herceptin Drugs 0.000 claims 1
- 230000003054 hormonal effect Effects 0.000 claims 1
- 238000001794 hormone therapy Methods 0.000 claims 1
- 229960003685 imatinib mesylate Drugs 0.000 claims 1
- 238000003316 immunomagnetic separation method Methods 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 238000011534 incubation Methods 0.000 claims 1
- 208000030776 invasive breast carcinoma Diseases 0.000 claims 1
- 229940084651 iressa Drugs 0.000 claims 1
- 229960004891 lapatinib Drugs 0.000 claims 1
- 229960000681 leflunomide Drugs 0.000 claims 1
- 210000002751 lymph Anatomy 0.000 claims 1
- 230000002934 lysing effect Effects 0.000 claims 1
- 239000012528 membrane Substances 0.000 claims 1
- 206010061289 metastatic neoplasm Diseases 0.000 claims 1
- LBWFXVZLPYTWQI-IPOVEDGCSA-N n-[2-(diethylamino)ethyl]-5-[(z)-(5-fluoro-2-oxo-1h-indol-3-ylidene)methyl]-2,4-dimethyl-1h-pyrrole-3-carboxamide;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C LBWFXVZLPYTWQI-IPOVEDGCSA-N 0.000 claims 1
- YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 claims 1
- 210000002445 nipple Anatomy 0.000 claims 1
- 102000037979 non-receptor tyrosine kinases Human genes 0.000 claims 1
- 108091008046 non-receptor tyrosine kinases Proteins 0.000 claims 1
- 108020004017 nuclear receptors Proteins 0.000 claims 1
- 230000003647 oxidation Effects 0.000 claims 1
- 238000007254 oxidation reaction Methods 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 239000000123 paper Substances 0.000 claims 1
- 229960005079 pemetrexed Drugs 0.000 claims 1
- 210000002381 plasma Anatomy 0.000 claims 1
- 150000003058 platinum compounds Chemical class 0.000 claims 1
- 102000027426 receptor tyrosine kinases Human genes 0.000 claims 1
- 108091008598 receptor tyrosine kinases Proteins 0.000 claims 1
- 210000003296 saliva Anatomy 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 190014017285 satraplatin Chemical compound 0.000 claims 1
- 229960005399 satraplatin Drugs 0.000 claims 1
- 229940095743 selective estrogen receptor modulator Drugs 0.000 claims 1
- 239000000333 selective estrogen receptor modulator Substances 0.000 claims 1
- 229950003647 semaxanib Drugs 0.000 claims 1
- 210000002966 serum Anatomy 0.000 claims 1
- IVDHYUQIDRJSTI-UHFFFAOYSA-N sorafenib tosylate Chemical compound [H+].CC1=CC=C(S([O-])(=O)=O)C=C1.C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 IVDHYUQIDRJSTI-UHFFFAOYSA-N 0.000 claims 1
- 150000003431 steroids Chemical class 0.000 claims 1
- 229960001796 sunitinib Drugs 0.000 claims 1
- WINHZLLDWRZWRT-ATVHPVEESA-N sunitinib Chemical compound CCN(CC)CCNC(=O)C1=C(C)NC(\C=C/2C3=CC(F)=CC=C3NC\2=O)=C1C WINHZLLDWRZWRT-ATVHPVEESA-N 0.000 claims 1
- 229940034785 sutent Drugs 0.000 claims 1
- 229940120982 tarceva Drugs 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- RCINICONZNJXQF-XAZOAEDWSA-N taxol® Chemical compound O([C@@H]1[C@@]2(CC(C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3(C21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-XAZOAEDWSA-N 0.000 claims 1
- 229940063683 taxotere Drugs 0.000 claims 1
- 229960000235 temsirolimus Drugs 0.000 claims 1
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 229960005267 tositumomab Drugs 0.000 claims 1
- 229960000575 trastuzumab Drugs 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 229940094060 tykerb Drugs 0.000 claims 1
- 210000002700 urine Anatomy 0.000 claims 1
- 229960005486 vaccine Drugs 0.000 claims 1
- LLDWLPRYLVPDTG-UHFFFAOYSA-N vatalanib succinate Chemical compound OC(=O)CCC(O)=O.C1=CC(Cl)=CC=C1NC(C1=CC=CC=C11)=NN=C1CC1=CC=NC=C1 LLDWLPRYLVPDTG-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (11)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US3131908P | 2008-02-25 | 2008-02-25 | |
| US61/031,319 | 2008-02-25 | ||
| US10640408P | 2008-10-17 | 2008-10-17 | |
| US61/106,404 | 2008-10-17 | ||
| US10838408P | 2008-10-24 | 2008-10-24 | |
| US61/108,384 | 2008-10-24 | ||
| US11790808P | 2008-11-25 | 2008-11-25 | |
| US61/117,908 | 2008-11-25 | ||
| US14055808P | 2008-12-23 | 2008-12-23 | |
| US61/140,558 | 2008-12-23 | ||
| PCT/US2009/035013 WO2009108637A1 (en) | 2008-02-25 | 2009-02-24 | Drug selection for breast cancer therapy using antibody-based arrays |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013102165A Division JP5852047B2 (ja) | 2008-02-25 | 2013-05-14 | 抗体に基づくアレイを用いた乳癌療法のための薬物選択 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2011514522A JP2011514522A (ja) | 2011-05-06 |
| JP2011514522A5 true JP2011514522A5 (enExample) | 2012-04-12 |
| JP5414701B2 JP5414701B2 (ja) | 2014-02-12 |
Family
ID=40599946
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2010547852A Expired - Fee Related JP5414701B2 (ja) | 2008-02-25 | 2009-02-24 | 抗体に基づくアレイを用いた乳癌療法のための薬物選択 |
| JP2013102165A Expired - Fee Related JP5852047B2 (ja) | 2008-02-25 | 2013-05-14 | 抗体に基づくアレイを用いた乳癌療法のための薬物選択 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013102165A Expired - Fee Related JP5852047B2 (ja) | 2008-02-25 | 2013-05-14 | 抗体に基づくアレイを用いた乳癌療法のための薬物選択 |
Country Status (12)
| Country | Link |
|---|---|
| US (4) | US8163499B2 (enExample) |
| EP (3) | EP2250498B1 (enExample) |
| JP (2) | JP5414701B2 (enExample) |
| CN (2) | CN103399144B (enExample) |
| AU (1) | AU2009219437B2 (enExample) |
| CA (2) | CA2716826C (enExample) |
| DK (2) | DK2602623T3 (enExample) |
| ES (3) | ES2553390T3 (enExample) |
| IL (3) | IL207637A (enExample) |
| MX (1) | MX2010009140A (enExample) |
| NZ (3) | NZ587420A (enExample) |
| WO (1) | WO2009108637A1 (enExample) |
Families Citing this family (96)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2557286T3 (es) | 2003-03-03 | 2016-01-25 | Dyax Corp. | Usos de péptidos que se unen específicamente al receptor del HGF (cMet) |
| NZ556673A (en) | 2005-02-03 | 2010-03-26 | Gen Hospital Corp | Method for treating gefitinib and/or erlotinib resistant cancer with an EGFR inhibitor |
| EP3488866A1 (en) | 2005-11-04 | 2019-05-29 | Wyeth LLC | Antineoplastic combinations with mtor inhibitor, herceptin, and/or hki-272 |
| BRPI0717416A2 (pt) | 2006-09-21 | 2013-11-12 | Prometheus Lab Inc | Método para realizar um imunoensaio complexo de alta produtividade, e, arranjo |
| NZ582618A (en) | 2007-07-13 | 2012-07-27 | Prometheus Lab Inc | Drug selection for lung cancer therapy using antibody-based arrays |
| US8022216B2 (en) | 2007-10-17 | 2011-09-20 | Wyeth Llc | Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof |
| ES2553390T3 (es) | 2008-02-25 | 2015-12-09 | Nestec S.A. | Método para la detección de receptores truncados intracelulares |
| ES2531322T3 (es) | 2008-06-17 | 2015-03-13 | Wyeth Llc | Combinaciones antineoplásicas que contienen HKI-272 y vinorelbina |
| EP3175853B1 (en) | 2008-08-04 | 2023-11-01 | Wyeth LLC | Antineoplastic combinations of neratinib and capecitabine |
| EP3216874A1 (en) | 2008-09-05 | 2017-09-13 | TOMA Biosciences, Inc. | Methods for stratifying and annotating cancer drug treatment options |
| WO2010085845A1 (en) * | 2009-01-28 | 2010-08-05 | The University Of Queensland | Cancer therapy and/or diagnosis |
| PT3000467T (pt) | 2009-04-06 | 2023-03-30 | Wyeth Llc | Regime de tratamento utilizando neratinib para o cancro de mama |
| NZ596468A (en) * | 2009-05-14 | 2013-11-29 | Nestec Sa | Biomarkers for determining sensitivity of breast cancer cells to her2-targeted therapy |
| EP2473854B1 (en) * | 2009-06-23 | 2017-08-23 | Fundação D. Anna de Sommer Champalimaud e Dr. Carlos Montez Champalimaud | Systems and methods for treating, diagnosing and predicting the response to therapy of breast cancer |
| JP5795311B2 (ja) * | 2009-07-15 | 2015-10-14 | ネステク ソシエテ アノニム | 抗体ベースのアレイを使用する胃癌療法のための薬物選択 |
| WO2011015920A2 (en) * | 2009-08-03 | 2011-02-10 | Avesthagen Limited | A highly efficient process of purification and production of recombinant trastuzumab |
| WO2011015921A1 (en) * | 2009-08-03 | 2011-02-10 | Avesthagen Limited | A highly efficient process of purification and production of recombinant cetuximab |
| WO2011034919A2 (en) * | 2009-09-15 | 2011-03-24 | H. Lee Moffitt Cancer Center And Research Institute, Inc. | Sh2 domain profiling to characterize tyrosine phosphorylation signaling in cancer |
| DK2491385T3 (en) | 2009-10-20 | 2017-08-28 | Diatech Holdings Inc | PROXIMITY-MEDIED ASSAYS FOR DETECTING ONCOGEN FUSION PROTEINS |
| RU2558931C2 (ru) | 2010-01-12 | 2015-08-10 | Нестек С.А. | Способы предсказания ответа трижды негативного рака молочной железы на терапию |
| JP6126382B2 (ja) * | 2010-01-13 | 2017-05-10 | ワイス・エルエルシー | 腫瘍を正確に識別し、かつＰＡＮ‐ＥｒｂＢ阻害剤に対する薬物応答を予測するＰＴＥＮタンパク質発現におけるカットポイント |
| CA2804269A1 (en) * | 2010-07-07 | 2012-01-12 | The Regents Of The University Of Michigan | Diagnosis and treatment of breast cancer |
| TW201302793A (zh) | 2010-09-03 | 2013-01-16 | Glaxo Group Ltd | 新穎之抗原結合蛋白 |
| AU2011305445B2 (en) | 2010-09-24 | 2017-03-16 | The Board Of Trustees Of The Leland Stanford Junior University | Direct capture, amplification and sequencing of target DNA using immobilized primers |
| SG191230A1 (en) | 2010-12-23 | 2013-07-31 | Nestec Sa | Drug selection for malignant cancer therapy using antibody-based arrays |
| US9962361B2 (en) | 2011-01-03 | 2018-05-08 | The William M. Yarbrough Foundation | Isothiocyanate functional surfactants, formulations incorporating the same, and associated methods of use |
| US9719995B2 (en) | 2011-02-03 | 2017-08-01 | Pierian Holdings, Inc. | Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling |
| US9532969B2 (en) | 2011-02-08 | 2017-01-03 | The William M. Yarbrough Foundation | Method for treating psoriasis |
| MX343327B (es) | 2011-02-17 | 2016-11-01 | Nestec Sa | Ensayos para detectar autoanticuerpos contra farmacos anti-tnfa. |
| BR112013020992A2 (pt) | 2011-02-17 | 2016-10-11 | Nestec Sa | aparelho e método para isolamento de leucócitos e células tumorosas por meio de filtração |
| EP2681552A2 (en) | 2011-03-02 | 2014-01-08 | Nestec S.A. | Prediction of drug sensitivity of lung tumors based on molecular and genetic signatures |
| KR20140020318A (ko) | 2011-04-04 | 2014-02-18 | 네스텍 소시에테아노님 | 위암 환자의 생존률 예측 및 개선 방법 |
| EP2670866A4 (en) * | 2011-04-05 | 2015-09-02 | Translational Genomics Res Inst | BIOMARKERS AND METHOD OF APPLICATION THEREFOR |
| CA3295783A1 (en) | 2011-05-10 | 2026-03-02 | Prometheus Laboratories, Inc. | Methods of disease activity profiling for personalized therapy management |
| EP2744912B1 (en) | 2011-08-18 | 2016-11-02 | Nestec S.A. | Compositions and methods for detecting allelic variants |
| KR101851425B1 (ko) | 2011-09-02 | 2018-04-23 | 네스텍 소시에테아노님 | 치료 효능 결정을 위한 신호 경로 단백질의 프로파일링 |
| AU2012332481B2 (en) * | 2011-11-04 | 2017-01-19 | Invivis Sas | Assay for predictive biomarkers of anti-estrogen efficacy |
| EP2788752B1 (en) * | 2011-12-05 | 2018-10-03 | Pierian Holdings, Inc. | Method of therapy selection for patients with lung cancer |
| CN103157109A (zh) * | 2011-12-12 | 2013-06-19 | 中国科学院生物物理研究所 | Cd146及其抗体诊断和治疗三阴性乳腺癌的应用 |
| MX355567B (es) * | 2011-12-30 | 2018-04-23 | Quest Diagnostics Invest Inc | Aptameros y metodos de diagnostico para detectar el receptor de egf. |
| US20130330761A1 (en) | 2012-06-12 | 2013-12-12 | Celcuity, LLC | Whole cell assays and methods |
| US10434081B2 (en) | 2012-07-26 | 2019-10-08 | The William M. Yarbrough Foundation | Inhibitors of macrophage migration inhibitory factor |
| US10441561B2 (en) | 2012-07-26 | 2019-10-15 | The William M. Yanbrough Foundation | Method for treating benign prostatic hyperplasia (BPH), prostatitis, and prostate cancer |
| US10434082B2 (en) | 2012-07-26 | 2019-10-08 | The William M. Yarbrough Foundation | Isothiocyanate functional compounds augmented with secondary antineoplastic medicaments and associated methods for treating neoplasms |
| US10335387B2 (en) | 2012-07-26 | 2019-07-02 | The William M. Yarbrough Foundation | Method for treating infectious diseases with isothiocyanate functional compounds |
| US20150212087A1 (en) * | 2012-07-27 | 2015-07-30 | Centre Leon Berard | Detection of the ERalpha/Src/PI3K Complex as Predictive Marker in Breast Cancer |
| ES2638971T3 (es) | 2012-10-05 | 2017-10-24 | Nestec S.A. | Métodos para predecir y monitorizar la cicatrización de la mucosa |
| CA3215087A1 (en) * | 2013-01-03 | 2014-07-10 | Meso Scale Technologies, Llc | Assay panels |
| WO2014122600A1 (en) | 2013-02-05 | 2014-08-14 | Nestec S.A. | Methods of selecting combination therapy for colorectal cancer patients |
| EP2954328A1 (en) | 2013-02-05 | 2015-12-16 | Nestec S.A. | Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling |
| HK1218939A1 (zh) | 2013-02-05 | 2017-03-17 | Nestec S.A. | 用於非小细胞肺癌疗法的药物选择 |
| CN117288934A (zh) | 2013-03-13 | 2023-12-26 | 中尺度技术有限责任公司 | 改进的测定方法 |
| US10114015B2 (en) | 2013-03-13 | 2018-10-30 | Meso Scale Technologies, Llc. | Assay methods |
| US10041125B2 (en) | 2013-03-15 | 2018-08-07 | Janssen Pharmaceutica Nv | Assay for predictive biomarkers |
| CN105283454B (zh) | 2013-04-12 | 2019-10-29 | 阿萨纳生物科技有限责任公司 | 作为ras/raf/mek/erk和pi3k/akt/pten/mtor通路双重抑制剂的喹唑啉和氮杂喹唑啉 |
| EP3373010A1 (en) | 2013-05-21 | 2018-09-12 | Pierian Holdings, Inc. | Method for selecting a therapy for the treatment of colorectal cancer patients |
| KR20160026909A (ko) | 2013-07-09 | 2016-03-09 | 네스텍 소시에테아노님 | 미세유체 협동 효소 증강 반응성(ceer) 면역검정 |
| WO2015028974A2 (en) | 2013-08-30 | 2015-03-05 | Nestec S.A. | Polyp recurrence |
| AU2014333815B2 (en) * | 2013-10-11 | 2020-07-09 | Nihon University School Of Medicine | Multiplex HER2 and estrogen receptor co-staining assays for detecting tumor heterogeneity |
| BR112016008202A2 (pt) * | 2013-10-23 | 2017-10-03 | Univ Oregon Health & Science | Métodos de determinação do prognóstico do câncer de mama |
| WO2015083085A1 (en) | 2013-12-03 | 2015-06-11 | Nestec S.A. | Signaling pathways in tissues from inflammatory bowel disease patients |
| WO2015089380A2 (en) | 2013-12-12 | 2015-06-18 | Celcuity Llc | Assays and methods for determining the responsiveness of an individual subject to a therapeutic agent |
| US9730935B2 (en) * | 2013-12-13 | 2017-08-15 | The Board Of Trustees Of The Leland Stanford Junior University | Targeting a non-canonical notch signaling pathway for cancer treatment |
| US20160334389A1 (en) * | 2014-01-14 | 2016-11-17 | Won Cheol Choi | Method for screening cancer prevention agent or anticancer agent using morphological characteristics of luterial |
| WO2015110989A1 (en) | 2014-01-23 | 2015-07-30 | Nestec S.A. | Biomarker panel for assessment of mucosal healing |
| WO2015166461A1 (en) | 2014-05-01 | 2015-11-05 | Nestec S.A. | Methods of selecting treatment regimen using tnf alpha and anti-tnf alpha drug levels |
| KR102757668B1 (ko) | 2014-05-15 | 2025-01-21 | 메소 스케일 테크놀러지즈, 엘엘시 | 개선된 분석 방법 |
| CN104083762A (zh) * | 2014-06-27 | 2014-10-08 | 中国科学院生物物理研究所 | 用于阻断Netrin-1与CD146之间的相互作用的试剂及其肿瘤治疗用途 |
| MX2017004742A (es) | 2014-10-20 | 2017-07-20 | Nestec Sa | Métodos para la predicción de niveles de farmacos anti-tnf alfa y formación de autoanticuerpos. |
| JP2018504584A (ja) | 2014-12-02 | 2018-02-15 | ネステク ソシエテ アノニム | 過敏性腸疾患患者を治療するためのベドリズマブの投与計画を確立する方法 |
| EP3699589A1 (en) * | 2014-12-12 | 2020-08-26 | Celcuity Inc. | Methods of measuring erbb signaling pathway activity to diagnose and treat cancer patients |
| CN107430121B (zh) | 2015-03-13 | 2020-06-23 | 希森美康株式会社 | 受试物质的检测方法及在该方法中使用的试剂盒 |
| EP3363911B1 (en) * | 2015-10-14 | 2024-09-25 | Nitto Boseki Co., Ltd. | Method for determining drug-sensitive human breast cancer cells by analysis method in which measurement of activity of two types of protein kinase is used |
| CN109789204A (zh) * | 2016-05-31 | 2019-05-21 | 雀巢产品技术援助有限公司 | 基于her2和her3通路亚型选择乳癌患者药物疗法的方法 |
| CN107727752B (zh) * | 2016-08-12 | 2019-11-08 | 北大方正集团有限公司 | 免疫抑制剂依维莫司的分析方法 |
| JP6779483B2 (ja) | 2016-09-29 | 2020-11-04 | 住友ゴム工業株式会社 | 医療用検査装置及び細胞検査方法 |
| JP6518985B2 (ja) * | 2016-09-29 | 2019-05-29 | 住友ゴム工業株式会社 | がん細胞捕捉方法 |
| CN106645728A (zh) * | 2016-11-09 | 2017-05-10 | 百奥森（江苏）食品安全科技有限公司 | 一种食品中氟喹诺酮类药物的检测试剂盒 |
| WO2018103834A1 (en) * | 2016-12-07 | 2018-06-14 | Fundació Privada Institut D'investigació Oncológica De Vall D'hebron | Her2 as a predictor of response to dual her2 blockade in the absence of cytotoxic therapy |
| EP3879269A3 (en) | 2017-03-20 | 2021-11-17 | Celcuity Inc. | Methods of measuring signaling pathway activity for selection of therapeutic agents |
| SI3612519T1 (sl) | 2017-04-18 | 2022-04-29 | Eli Lilly And Company | Fenil-2-hidroksi-acetilamino-2-metil-fenilne spojine |
| KR20200009095A (ko) | 2017-05-31 | 2020-01-29 | 프로메테우스 바이오사이언시즈, 인크. | 크론병 환자에서 점막 치유를 평가하는 방법 |
| JP7328960B2 (ja) | 2017-10-10 | 2023-08-17 | プロメテウス バイオサイエンシーズ インコーポレイテッド | ベドリズマブ処置をモニタリングするための方法 |
| JP7557367B2 (ja) * | 2017-11-17 | 2024-09-27 | アイオバンス バイオセラピューティクス，インコーポレイテッド | 細針吸引及び小生検からのｔｉｌ拡大培養 |
| JP7158671B2 (ja) | 2018-02-14 | 2022-10-24 | 住友ゴム工業株式会社 | 特定細胞捕捉方法 |
| JP7109719B2 (ja) | 2018-02-14 | 2022-08-01 | 住友ゴム工業株式会社 | 特定細胞捕捉方法 |
| KR102897382B1 (ko) * | 2018-03-26 | 2025-12-08 | 이칸 스쿨 오브 메디슨 엣 마운트 시나이 | 미세 잔존 암을 치료하는 방법 |
| WO2019200326A1 (en) * | 2018-04-13 | 2019-10-17 | Rarecyte, Inc. | Kits for labeling of biomarkers and methods of using the same |
| US11614440B2 (en) | 2019-01-24 | 2023-03-28 | Sumitomo Rubber Industries, Ltd. | Specific cell fractionating and capturing methods |
| CN120098057A (zh) | 2019-03-01 | 2025-06-06 | 中尺度技术有限责任公司 | 用于免疫方法的被电化学发光标记的探针、使用这类探针的方法和包含这类探针的试剂盒 |
| JP6886667B2 (ja) * | 2019-03-27 | 2021-06-16 | 住友ゴム工業株式会社 | がん細胞捕捉方法 |
| WO2021041973A1 (en) | 2019-08-29 | 2021-03-04 | Hibercell, Inc. | Perk inhibiting compounds |
| TW202229343A (zh) | 2020-08-21 | 2022-08-01 | 美商健臻公司 | Fgfr3抗體及使用方法 |
| AU2022304570A1 (en) | 2021-06-28 | 2024-01-18 | Meso Scale Technologies, Llc. | Methods, compositions, and kits for assay signal amplification |
| CN113929764B (zh) * | 2021-10-15 | 2023-12-29 | 中山大学孙逸仙纪念医院 | 一种乳腺叶状肿瘤分子标志物cd146及其应用 |
| CN116148366B (zh) * | 2021-11-23 | 2024-12-10 | 中国科学院大连化学物理研究所 | 一种基于活性氧响应载体的蛋白质复合物原位分析方法 |
Family Cites Families (133)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4233402A (en) | 1978-04-05 | 1980-11-11 | Syva Company | Reagents and method employing channeling |
| US5516931A (en) * | 1982-02-01 | 1996-05-14 | Northeastern University | Release tag compounds producing ketone signal groups |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4690890A (en) | 1984-04-04 | 1987-09-01 | Cetus Corporation | Process for simultaneously detecting multiple antigens using dual sandwich immunometric assay |
| SE8500817D0 (sv) | 1985-02-20 | 1985-02-20 | Lars Jonsson | Halvoppet anestesisystem |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
| US4959306A (en) * | 1986-11-28 | 1990-09-25 | Sclavo, Inc. | Labeling design for a binding assay reagent |
| US4975532A (en) | 1986-11-28 | 1990-12-04 | Sclavo, Inc. | Method to derivatize dextran |
| JPH01163661A (ja) | 1987-10-02 | 1989-06-27 | E I Du Pont De Nemours & Co | ＩｇＧ捕捉抗体および多重単クローン性抗体検出系を用いたイムノアツセイ |
| US4855241A (en) * | 1988-05-26 | 1989-08-08 | Washington University | Tumor diagnostic method |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
| US5192660A (en) | 1989-04-24 | 1993-03-09 | The United States Of America As Represented By The Department Of Health And Human Services | ELISA methods for the determination of human platelet derived growth factor (PDGF) dimer forms present in human tissues and fluids |
| US5089419A (en) | 1989-08-07 | 1992-02-18 | International Canine Genetics | Detection of pregnancy by identification of the c peptide of relaxin in the urine of animals |
| US5120660A (en) | 1989-12-05 | 1992-06-09 | International Canine Genetics, Inc. | Method for canine fertility detection |
| US5532138A (en) | 1990-04-26 | 1996-07-02 | Behringwerke Ag | Method and kits for determining peroxidatively active catalysts |
| US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
| FR2672128B1 (fr) | 1991-01-28 | 1995-08-18 | Cis Bio Int | Procede de mesure de la luminescence emise dans un dosage par luminescence. |
| US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
| US6251581B1 (en) | 1991-05-22 | 2001-06-26 | Dade Behring Marburg Gmbh | Assay method utilizing induced luminescence |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| FI941572L (fi) | 1991-10-07 | 1994-05-27 | Oncologix Inc | Anti-erbB-2-monoklonaalisten vasta-aineiden yhdistelmä ja käyttömenetelmä |
| WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
| CA2372813A1 (en) | 1992-02-06 | 1993-08-19 | L.L. Houston | Biosynthetic binding protein for cancer marker |
| EP0626012B1 (en) | 1992-02-11 | 2003-07-09 | Cell Genesys, Inc. | Homogenotization of gene-targeting events |
| US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
| US5332662A (en) | 1992-07-31 | 1994-07-26 | Syntex (U.S.A.) Inc. | Methods for determining peroxidatively active substances |
| DE69308573T2 (de) | 1992-08-17 | 1997-08-07 | Genentech Inc | Bispezifische immunoadhesine |
| JPH06109734A (ja) | 1992-09-30 | 1994-04-22 | S R L:Kk | 抗原の測定方法 |
| US6201109B1 (en) | 1993-01-13 | 2001-03-13 | Dade Behring Marburg Gmbh | Assay for bone alkaline phosphatase |
| WO1995006877A1 (en) | 1993-09-03 | 1995-03-09 | Behringwerke Ag | Fluorescent oxygen channeling immunoassays |
| JP3825815B2 (ja) | 1994-01-31 | 2006-09-27 | 信義 清水 | 上皮細胞増殖因子レセプターに対するモノクローナル抗体の結合体ならびにその複合体およびその細胞への嵌入方法 |
| US5807522A (en) | 1994-06-17 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods for fabricating microarrays of biological samples |
| FI98961C (fi) | 1994-08-26 | 1997-09-10 | Medix Biochemica Ab Oy | Menetelmät ja määritysvälineet parodontaalisairauden aktiivisuuden ja/tai peri-implantiitin ja/tai niiden kohonneen riskin diagnosoimiseksi |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
| US5876944A (en) | 1996-06-10 | 1999-03-02 | Bayer Corporation | Method for amplification of the response signal in a sandwich immunoassay |
| US20040023375A1 (en) | 2002-07-30 | 2004-02-05 | Precision Therapeutics, Inc. | Method for preparing cell cultures from biological specimens for chemotherapeutic and other assays |
| US5728541A (en) | 1996-07-12 | 1998-03-17 | Precision Therapeutics, Inc. | Method for preparing cell cultures from biologial specimens for chemotherapeutic and other assays |
| US6416967B2 (en) | 1996-07-12 | 2002-07-09 | Precision Therapeutics, Inc. | Method of using multicellular particulates to analyze malignant or hyperproliferative tissue |
| US6057098A (en) | 1997-04-04 | 2000-05-02 | Biosite Diagnostics, Inc. | Polyvalent display libraries |
| US6780582B1 (en) | 1998-07-14 | 2004-08-24 | Zyomyx, Inc. | Arrays of protein-capture agents and methods of use thereof |
| US6897073B2 (en) | 1998-07-14 | 2005-05-24 | Zyomyx, Inc. | Non-specific binding resistant protein arrays and methods for making the same |
| US6197599B1 (en) | 1998-07-30 | 2001-03-06 | Guorong Chin | Method to detect proteins |
| US6541214B1 (en) * | 1998-11-13 | 2003-04-01 | Oregon Heath Science University | N-terminally truncated HER-2/neu protein as a cancer prognostic indicator |
| RU2165081C2 (ru) | 1999-01-05 | 2001-04-10 | Ставропольский научно-исследовательский противочумный институт | Способ индикации микроорганизмов |
| US6335173B1 (en) | 1999-01-12 | 2002-01-01 | Verve, Ltd. C/O James Bell | Methods for detecting an analyte of interest using tyramide coating technology |
| GB9901072D0 (en) | 1999-01-19 | 1999-03-10 | Imp Cancer Res Tech | Methods for detecting changes to a macromolecular component of a cell |
| US6972198B2 (en) | 1999-02-26 | 2005-12-06 | Cyclacel, Ltd. | Methods and compositions using protein binding partners |
| RU2149404C1 (ru) | 1999-03-24 | 2000-05-20 | Московский НИИ глазных болезней им. Гельмгольца | Способ прогнозирования клинического течения увеальной меланомы |
| US6322980B1 (en) | 1999-04-30 | 2001-11-27 | Aclara Biosciences, Inc. | Single nucleotide detection using degradation of a fluorescent sequence |
| US6627400B1 (en) | 1999-04-30 | 2003-09-30 | Aclara Biosciences, Inc. | Multiplexed measurement of membrane protein populations |
| US6649351B2 (en) | 1999-04-30 | 2003-11-18 | Aclara Biosciences, Inc. | Methods for detecting a plurality of analytes by mass spectrometry |
| DE19926010C2 (de) | 1999-06-08 | 2003-01-30 | Bundesdruckerei Gmbh | Wert- und Sicherheitsdokument mit Sicherheitsmerkmal mit Piezo-Effekt-basierten Eigenschaften und dazugehöriges Nachweisverfahren |
| US7179638B2 (en) | 1999-07-30 | 2007-02-20 | Large Scale Biology Corporation | Microarrays and their manufacture by slicing |
| US7033781B1 (en) * | 1999-09-29 | 2006-04-25 | Diversa Corporation | Whole cell engineering by mutagenizing a substantial portion of a starting genome, combining mutations, and optionally repeating |
| AU1630501A (en) * | 1999-10-08 | 2001-04-23 | Superarray, Inc. | Compositions and methods for detecting protein modification and enzymatic activity |
| CA2385614A1 (en) | 1999-10-13 | 2001-04-19 | Timothy Johann | Multiplex cytokine analysis |
| US7537938B2 (en) | 2000-04-28 | 2009-05-26 | Monogram Biosciences, Inc. | Biomarker detection in circulating cells |
| US6511809B2 (en) | 2000-06-13 | 2003-01-28 | E. I. Du Pont De Nemours And Company | Method for the detection of an analyte by means of a nucleic acid reporter |
| CA2418105A1 (en) | 2000-08-03 | 2002-02-14 | Massachusetts Institute Of Technology | Microarrays of functional biomolecules, and uses therefor |
| US7785810B2 (en) * | 2000-09-09 | 2010-08-31 | The Research Foundation Of State University Of New York | Method and compositions for isolating metastatic cancer cells, and use in measuring metastatic potential of a cancer thereof |
| US6797481B1 (en) | 2000-10-17 | 2004-09-28 | Dade Behring Marburg Gmbh | Simultaneous screening of multiple analytes |
| US7635571B2 (en) | 2000-12-07 | 2009-12-22 | Siemens Healthcare Diagnostics Products Gmbh | Amplified signal in binding assays |
| DE10064827A1 (de) | 2000-12-22 | 2002-06-27 | Dade Behring Marburg Gmbh | Nachweisverfahren |
| US20070111944A1 (en) * | 2001-02-16 | 2007-05-17 | Scrofani Sergio D B | Purification of vascular endothelial growth factor-B |
| US20020168641A1 (en) | 2001-03-09 | 2002-11-14 | Bruce Mortensen | Fluorescein-cyanine 5 as a fluorescence resonance energy transfer pair |
| US20020142361A1 (en) | 2001-03-27 | 2002-10-03 | Emmert-Buck Michael R. | Biodetection method |
| AU2002303384A1 (en) | 2001-04-17 | 2002-10-28 | William J. Dower | Epitope-captured antibody display |
| US20040265923A1 (en) | 2001-05-03 | 2004-12-30 | James Gilmore | Method and apparatus to determine the performance of protein arrays |
| WO2002103321A2 (en) | 2001-06-14 | 2002-12-27 | Anadys Pharmaceuticals, Inc. | Methods of screening for ligands of target molecules |
| US7381535B2 (en) | 2002-07-10 | 2008-06-03 | The Board Of Trustees Of The Leland Stanford Junior | Methods and compositions for detecting receptor-ligand interactions in single cells |
| US7695926B2 (en) | 2001-07-10 | 2010-04-13 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for detecting receptor-ligand interactions in single cells |
| JP2003028874A (ja) * | 2001-07-12 | 2003-01-29 | Mitsubishi Chemicals Corp | ２段階酵素反応を用いた測定対象物質の測定法 |
| AU2002322461B2 (en) | 2001-07-12 | 2007-12-06 | Vegenics Limited | Lymphatic endothelial cells materials and methods |
| US8323903B2 (en) | 2001-10-12 | 2012-12-04 | Life Technologies Corporation | Antibody complexes and methods for immunolabeling |
| US20050069962A1 (en) | 2001-10-12 | 2005-03-31 | Archer Robert M | Antibody complexes and methods for immunolabeling |
| AU2002363530A1 (en) | 2001-11-07 | 2003-05-19 | Sensor Technologies Llc | Method of identifying energy transfer sensors for analytes |
| EP1478765A4 (en) | 2002-03-05 | 2006-12-06 | Aclara Biosciences Inc | MULTIPLEX ANALYSIS USING MEMBRANE-FIXED SENSITIZERS |
| AU2003223495A1 (en) * | 2002-04-05 | 2003-10-27 | Cell Signaling Technology, Inc. | Molecular profiling of disease and therapeutic response using phospho-specific antibodies |
| US20030190689A1 (en) * | 2002-04-05 | 2003-10-09 | Cell Signaling Technology,Inc. | Molecular profiling of disease and therapeutic response using phospho-specific antibodies |
| US20040229380A1 (en) | 2002-05-21 | 2004-11-18 | Po-Ying Chan-Hui | ErbB heterodimers as biomarkers |
| HUP0600340A3 (en) | 2002-07-15 | 2011-06-28 | Genentech Inc | Methods for identifying tumors that are responsive to treatment with anti-erbb2 antibodies |
| FR2843126B1 (fr) | 2002-08-01 | 2006-01-27 | Cis Bio Int | "methode de determination d'une activite enzymatique endoglycosidase" |
| US20040235002A1 (en) | 2002-09-20 | 2004-11-25 | Sangamo Biosciences, Inc. | Multiplex screening assays |
| US20030153013A1 (en) * | 2002-11-07 | 2003-08-14 | Ruo-Pan Huang | Antibody-based protein array system |
| WO2004053497A2 (en) * | 2002-12-11 | 2004-06-24 | Ventana Medical Systems, Inc. | Method for predicting the response to her2-directed therapy |
| WO2004071572A2 (en) | 2003-02-06 | 2004-08-26 | Genomic Health, Inc. | Gene expression markers for response to egfr inhibitor drugs |
| BRPI0408928A (pt) | 2003-04-01 | 2006-09-12 | Monogram Biosciences Inc | métodos para determinar uma situação de doença em um paciente, uma situação apoptótica de células em uma amostra, e uma situação de um cáncer em um paciente |
| US20040265938A1 (en) | 2003-06-25 | 2004-12-30 | Jose Remacle | Method for the determination of cell activation |
| US7279286B2 (en) | 2003-09-11 | 2007-10-09 | Sanofi-Aventis Deutschland Gmbh | High-throughput-assay with high sensitivity for measuring of the activity of β-adrenergic receptor kinase and for determining the impact of test substances on such activity |
| FI20031370A0 (fi) | 2003-09-23 | 2003-09-23 | Wallac Oy | Automaattinen hemoglobiinin määritysmenetelmä vastasyntyneiden seulontaan |
| WO2005037071A2 (en) | 2003-10-14 | 2005-04-28 | Monogram Biosciences, Inc. | Receptor tyrosine kinase signaling pathway analysis for diagnosis and therapy |
| ES2343840T3 (es) | 2003-11-04 | 2010-08-11 | Bayer Healthcare Llc | Procedimientos inmunohistoquimicos para supervisar los niveles de perk. |
| JP2007515957A (ja) * | 2003-12-12 | 2007-06-21 | バイエル・フアーマシユーチカルズ・コーポレーシヨン | ガンの予示及び予後ならびにガン治療の監視のための方法 |
| JP2007526460A (ja) | 2004-03-03 | 2007-09-13 | バイエル・テクノロジー・サービシーズ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 細胞集団のタンパク質発現プロファイルの作成のための分析用プラットフォームおよび方法 |
| JP5422120B2 (ja) | 2004-05-27 | 2014-02-19 | ザ リージェンツ オブ ザ ユニバーシティ オブ コロラド，ア ボディー コーポレイト | 癌患者による上皮成長因子受容体阻害薬に対する臨床転帰の予測方法 |
| SV2006002143A (es) | 2004-06-16 | 2006-01-26 | Genentech Inc | Uso de un anticuerpo para el tratamiento del cancer resistente al platino |
| US20060263837A1 (en) | 2004-06-17 | 2006-11-23 | Liu George D | Immunoassay system and method for detection of antigens |
| US20060024722A1 (en) | 2004-07-30 | 2006-02-02 | Mark Fischer-Colbrie | Samples for detection of oncofetal fibronectin and uses thereof |
| WO2006031815A2 (en) | 2004-09-13 | 2006-03-23 | Monogram Biosciences, Inc. | Methods and compositions for proximity assays |
| WO2006044748A2 (en) * | 2004-10-15 | 2006-04-27 | Monogram Biosciences, Inc. | RESPONSE PREDICTORS FOR ErbB PATHWAY-SPECIFIC DRUGS |
| WO2006045991A1 (en) | 2004-10-25 | 2006-05-04 | Astrazeneca Ab | Method to predict whether a tumor will react to a chemotherapeutic treatment |
| WO2006054991A1 (en) | 2004-11-17 | 2006-05-26 | Immunivest Corporation | Magnetic enrichment of circulating cells, fragments and debris for enabling hts proteomics and genomics in disease detection |
| WO2006055739A2 (en) | 2004-11-17 | 2006-05-26 | Robert Sack | Stationary phase antibody arrays for trace protein analysis |
| DE102004056794B4 (de) | 2004-11-24 | 2010-08-26 | Protagen Ag | Verwendung einer Anordnung und Verfahren zur Validierung von Bindern |
| WO2006105642A1 (en) | 2005-04-05 | 2006-10-12 | British Columbia Cancer Agency | Biomarkers for the detection of lung cancer and uses thereof |
| JP4851730B2 (ja) * | 2005-05-09 | 2012-01-11 | 小澤 滿 | 除塵加湿装置 |
| AR053272A1 (es) | 2005-05-11 | 2007-04-25 | Hoffmann La Roche | Determinacion de responsivos a la quimioterapia |
| US7771955B2 (en) | 2005-06-09 | 2010-08-10 | University Of Maryland | Affinity membrane for capture of a target biomolecule and formation thereof by site-directed immobilization of a capture biomolecule |
| JP2007089548A (ja) * | 2005-09-30 | 2007-04-12 | Univ Of Tokushima | シグナル増幅方法 |
| CN101008644A (zh) * | 2006-01-27 | 2007-08-01 | 陈云 | 功能性中枢神经损伤诊断检测用蛋白芯片及其制造方法 |
| US8367351B2 (en) * | 2006-05-05 | 2013-02-05 | Historx, Inc. | Methods for determining signal transduction activity in tumors |
| WO2008019375A2 (en) * | 2006-08-07 | 2008-02-14 | The Board Of Regents Of The University Of Texas System | Proteomic patterns of cancer prognostic and predictive signatures |
| BRPI0717416A2 (pt) | 2006-09-21 | 2013-11-12 | Prometheus Lab Inc | Método para realizar um imunoensaio complexo de alta produtividade, e, arranjo |
| CN104198705B (zh) | 2006-09-21 | 2017-06-09 | 雀巢产品技术援助有限公司 | 检测稀有循环细胞内多种信号转导分子的基于抗体的阵列 |
| BRPI0718413A2 (pt) * | 2006-10-23 | 2014-03-11 | The Uab Research Foundation | Métodos para prever a sensibilidade de uma célula concerosa a um primeiro agente anticâncer, para prever ou monitorar a eficácia de um agente anticâncer, e para determinar uma dose eficaz para um agente anticâncer, kit de detecção, e, sistema de ensaio multiplex |
| WO2008055314A1 (en) | 2006-11-10 | 2008-05-15 | Dimerix Bioscience Pty Ltd | Thyrotropin releasing hormone receptor-orexin receptor hetero-dimers/-oligomers |
| WO2008064884A1 (en) | 2006-11-28 | 2008-06-05 | U3 Pharma Gmbh | Activated her3 as a marker for predicting therapeutic efficacy |
| AU2008231393A1 (en) | 2007-03-27 | 2008-10-02 | Rosetta Genomics Ltd. | Gene expression signature for classification of cancers |
| JP2008292424A (ja) | 2007-05-28 | 2008-12-04 | Nippon Medical School | 腫瘍の検出方法 |
| NZ582618A (en) | 2007-07-13 | 2012-07-27 | Prometheus Lab Inc | Drug selection for lung cancer therapy using antibody-based arrays |
| EP2065475A1 (en) | 2007-11-30 | 2009-06-03 | Siemens Healthcare Diagnostics GmbH | Method for therapy prediction in tumors having irregularities in the expression of at least one VEGF ligand and/or at least one ErbB-receptor |
| ES2553390T3 (es) | 2008-02-25 | 2015-12-09 | Nestec S.A. | Método para la detección de receptores truncados intracelulares |
| US20120270745A1 (en) | 2009-07-15 | 2012-10-25 | Prometheus Laboratories Inc. | Drug selection for cancer therapy by profiling signal transduction proteins in ascites or pleural efflux samples |
| JP5795311B2 (ja) | 2009-07-15 | 2015-10-14 | ネステク ソシエテ アノニム | 抗体ベースのアレイを使用する胃癌療法のための薬物選択 |
| WO2012047294A2 (en) | 2010-10-06 | 2012-04-12 | Ludwig Institute For Cancer Research Ltd | Antibodies directed against hla-b27 homodimers and methods and uses thereof in diagnosis and therapy |
| US9719995B2 (en) | 2011-02-03 | 2017-08-01 | Pierian Holdings, Inc. | Drug selection for colorectal cancer therapy using receptor tyrosine kinase profiling |
| US20120231965A1 (en) | 2011-02-03 | 2012-09-13 | Prometheus Laboratories Inc. | Drug selection for colorectal cancer therapy using antibody-based arrays |
| US20130216523A1 (en) | 2011-03-31 | 2013-08-22 | Laboratory Corporation Of America Holdings | Methods for Facilitating Diagnosis, Prognosis and Treatment of Cancer by Detecting HER1 Expression |
| KR101851425B1 (ko) | 2011-09-02 | 2018-04-23 | 네스텍 소시에테아노님 | 치료 효능 결정을 위한 신호 경로 단백질의 프로파일링 |
-
2009
- 2009-02-24 ES ES12183659.7T patent/ES2553390T3/es active Active
- 2009-02-24 CN CN201310300562.3A patent/CN103399144B/zh not_active Expired - Fee Related
- 2009-02-24 ES ES13164311.6T patent/ES2545760T3/es active Active
- 2009-02-24 WO PCT/US2009/035013 patent/WO2009108637A1/en not_active Ceased
- 2009-02-24 CA CA2716826A patent/CA2716826C/en active Active
- 2009-02-24 NZ NZ587420A patent/NZ587420A/en not_active IP Right Cessation
- 2009-02-24 EP EP09715619A patent/EP2250498B1/en active Active
- 2009-02-24 EP EP12183659.7A patent/EP2602623B1/en not_active Not-in-force
- 2009-02-24 MX MX2010009140A patent/MX2010009140A/es active IP Right Grant
- 2009-02-24 AU AU2009219437A patent/AU2009219437B2/en not_active Ceased
- 2009-02-24 EP EP13164311.6A patent/EP2618146B1/en not_active Not-in-force
- 2009-02-24 JP JP2010547852A patent/JP5414701B2/ja not_active Expired - Fee Related
- 2009-02-24 NZ NZ617520A patent/NZ617520A/en not_active IP Right Cessation
- 2009-02-24 DK DK12183659.7T patent/DK2602623T3/en active
- 2009-02-24 CA CA2923248A patent/CA2923248A1/en not_active Abandoned
- 2009-02-24 CN CN200980114742.4A patent/CN102016581B/zh not_active Expired - Fee Related
- 2009-02-24 ES ES09715619T patent/ES2398618T3/es active Active
- 2009-02-24 NZ NZ600339A patent/NZ600339A/en not_active IP Right Cessation
- 2009-02-24 DK DK09715619.4T patent/DK2250498T3/da active
- 2009-07-28 US US12/511,017 patent/US8163499B2/en not_active Expired - Fee Related
-
2010
- 2010-08-16 IL IL207637A patent/IL207637A/en not_active IP Right Cessation
-
2012
- 2012-04-04 US US13/439,737 patent/US8609349B2/en not_active Expired - Fee Related
- 2012-11-05 IL IL222872A patent/IL222872A/en active IP Right Grant
-
2013
- 2013-03-14 IL IL225241A patent/IL225241A/en not_active IP Right Cessation
- 2013-05-14 JP JP2013102165A patent/JP5852047B2/ja not_active Expired - Fee Related
- 2013-11-26 US US14/091,114 patent/US9274116B2/en not_active Expired - Fee Related
-
2016
- 2016-01-12 US US14/993,813 patent/US10436786B2/en not_active Expired - Fee Related
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2558931C2 (ru) | Способы предсказания ответа трижды негативного рака молочной железы на терапию | |
| EP2788752B1 (en) | Method of therapy selection for patients with lung cancer | |
| DK2491385T3 (en) | PROXIMITY-MEDIED ASSAYS FOR DETECTING ONCOGEN FUSION PROTEINS | |
| JP6186575B2 (ja) | 治療有効性を判定するためのシグナル経路タンパク質のプロファイリング | |
| CN102016581B (zh) | 用抗体阵列选择乳腺癌治疗药物 | |
| JP2013508728A5 (enExample) | ||
| RU2013142450A (ru) | Выбор лекарственных средств для терапии рака легких с помощью матриц на основе антител | |
| JP2013517461A5 (enExample) | ||
| KR20140002711A (ko) | 항체-기반 어레이를 사용한 악성 암 치료를 위한 약물 선별법 | |
| CN103597354B (zh) | 用于预测和改善胃癌患者存活的方法 | |
| CA2908515A1 (en) | Systems and methods for facilitating diagnosis, prognosis and treatment of cancer based on detection of her3 activation | |
| WO2011109625A4 (en) | Methods for determining responsiveness to a drug based upon determination of ras mutation and/or ras amplification | |
| Dong et al. | Multiplex europium (III) nanoparticles immunochromatographic assay method for the detection of four nitrofuran metabolites in fish sample | |
| Lehmann-Che et al. | Cancer genomics guide clinical practice in personalized medicine | |
| Chen et al. | A washing-free and easy-to-operate fluorescent biosensor for highly efficient detection of breast cancer-derived exosomes | |
| Li et al. | Multifunctional gold nanoparticle based selective detection of esophageal squamous cell carcinoma cells using resonance Rayleigh scattering assay | |
| US10640830B2 (en) | Drug selection for non-small cell lung cancer therapy | |
| US11415584B2 (en) | Biomarkers, test method, and test kit for predicting therapeutic effect of anti-VEGFR-2 antibody drug | |
| JP6619339B2 (ja) | ポリープ再発 | |
| WO2014122600A1 (en) | Methods of selecting combination therapy for colorectal cancer patients |